The ultimate success of the Bristol-Myers’ Celgene purchase could hinge on one upcoming trial
Biggest life sciences M&A deal for nearly two decades may turn out to be a damp squib if Dr Reddy’s wins a suit relating to follow-on patents that cover flagship cancer treatment Revlimid
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.